The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1984-12

AUTHORS

Angus G. Dalgleish, Peter C. L. Beverley, Paul R. Clapham, Dorothy H. Crawford, Melvyn F. Greaves, Robin A. Weiss

ABSTRACT

Acquired immune deficiency syndrome (AIDS) is characterized by opportunistic infections and by ‘opportunistic neoplasms’ (for example, Kaposi's sarcoma)1. Persistent generalized lymphadenopathy (PGL) is epidemiologically associated with AIDS, especially in male homosexuals. A subset of T lymphocytes positive for the CD4 antigen2 (also termed T4 antigen), is depleted in AIDS and PGL patients. A retrovirus found in T-cell cultures from these patients3–5 is strongly implicated in the aetiology of AIDS because of the high frequency of isolation4 and the prevalence of specific antibodies6–8 in the patients. Here we have detected cell-surface receptors for the AIDS retrovirus (human T-cell leukaemia virus-III (HTLV-III) and lymphadenopathy-associated virus-1 (LAV-1) isolates) by testing the susceptibility of cells to infection with pseudotypes of vesicular stomatitis virus bearing retroviral envelope antigens, and by the formation of multinucleated syncytia on mixing virus-producing cells with receptor-bearing cells. Receptors were present only on cells expressing CD4 antigen; among 155 monoclonal antibodies tested, each of the 14 anti-CD4 antibodies inhibited formation of syncytia and blocked pseudotypes. Productive infection of CD4+ cells with HTLV-III or LAV-1 markedly reduced cell-surface expression of CD4. In contrast, receptors for HTLV-I and HTLV-II were not restricted to CD4+ cells, were not blocked by anti-CD4 antibodies; cells productively infected with HTLV-I and HTLV-II expressed surface CD4. Hence, we conclude that the CD4 antigen is an essential and specific component of the receptor for the causative agent of AIDS. More... »

PAGES

763-767

References to SciGraph publications

Journal

TITLE

Nature

ISSUE

5996

VOLUME

312

Related Patents

  • Isolated Peptides Derived From Human Immunodeficiency Virus Types 1 And 2 Containing Fusion Inhibitory Domains
  • Targeted Cytolysis Of Hiv-Infected Cells By Chimeric Cd4 Receptor-Bearing Cells
  • Immunoglobulin Chimeric Monomer-Dimer Hybrids
  • Contacting With Monoclonal Antibody Which Binds To Chemokine Receptor; Blocks Fusion And Inhibits Activation Of Inflammatory Response; Inhibiting Fusion Of Hiv-1 To Cd4+ Cells
  • Dual Inhibitors Of Hiv-1 Gp-120 Interactions
  • Drug Delivery Devices And Pharmaceutical Composition For Treatment Wasting Syndromes
  • Method For The Production Of Antibodies That Bind To Multiple Membrane Spanning Proteins
  • Nucleic Acids Encoding Self-Assembled, Non-Infectious, Non-Replicating, Immunogenic Retrovirus-Like Particles Comprising Modified Hiv Genomes And Chimeric Envelope Glycoproteins
  • Human Monoclonal Antibodies Directed Against The Transmembrane Glycoprotein (Gp41) Of Human Immunodeficiency Virus-1 (Hiv-1)
  • Methods For The Inhibition Of Epstein-Barr Virus Transmission Employing Anti-Viral Peptides Capable Of Abrogating Viral Fusion And Transmission
  • Method Of Raising Neutralizing Antibodies Against Hiv
  • Anti-Cd4 Antibody Homologs Useful In Prophylaxis And Treatment Of Aids, Arc And Hiv Infection
  • Microfluidic Particle-Analysis Systems
  • Compounds And Method Of Identifying, Synthesizing, Optimizing And Profiling Protein Modulators
  • Authentic Trimeric Hiv-1 Gp140 Envelope Glycoproteins Comprising A Long Linker And Tag
  • Clotting Factor-Fc Chimeric Proteins To Treat Hemophilia
  • Immunoglobulin Chimeric Monomer-Dimer Hybrids
  • Combined Therapy For Treatment Of Hiv Infection
  • Inhibition Of Hiv-1 Replication By Disruption Of The Processing Of The Viral Capsid-Spacer Peptide 1 Protein
  • Targeted Cytolysis Of Hiv-Infected Cells By Chimeric Cd4 Receptor-Bearing Cells
  • Pharmaceutical Being Used For Treating Hiv Infection, The Composition And Uses Thereof
  • Recombinantly Preparing Antibody Fusion For Targeting And/Or Treating Metabolic Disorders
  • Preventing The Viral Entry Process Into Target Cells, By Inhibiting The Binding Of Viral Surface Glycoprotein To Cell Surface Cd4, To Fusion Coreceptors Ccr5 Chemokine Receptors And The Transient Conformation Fusion Intermediate That Ultimately Folds Into A Conformation Capable Of Mediating Fusion
  • Cvn-12p1: A Recombinant Allosteric Lectin Antagonist Of Hiv-1 Envelope Gp120 Interactions
  • Anti-Ccr5 Antibody
  • Immunoglobulin Chimeric Monomer-Dimer Hybrids
  • Peptide Vaccines And Associated Methods For Protection Against Feline Leukemia Virus
  • Identifying Preferential Immunoglobulins For Use In Treatment And Prevention Of Infections And Cell Proliferative Disorders Via Repeated Screening Of Phage Library
  • Derivatives Of Soluble T-4
  • Designing A Soluble Full-Length Hiv-1 Gp41 Trimer
  • Multifunctional Self-Assembling Polymeric Nanosystems
  • Polypeptide; Genetic Engineering
  • Inhibiting Binding Of A Hiv Antigen To Receptors On Cells Of Mammals
  • Theramutein Modulators
  • Population Of T4-Lymphocytes Specific For The Lav-Virus, Method For Their Production And Their Use In The Production Of This Virus
  • Genetic Engineering; Desroying Infections; Antitumor, Anticancer Agents
  • Compositions For Inhibition Of Membrane Fusion-Associated Events, Including Influenza Virus Transmission
  • Human Immunodeficiency Virus Type 1 (Hiv-1)-Neutralizing Human Single-Chain Antibodies With Improved Breadth And Potency
  • Methods For Inhibition Of Membrane Fusion-Associated Events, Including Respiratory Syncytial Virus Transmission
  • Methods For Inhibition Of Membrane Fusion-Associated Events, Including Hiv Transmission
  • Methods For Treating An Immune Disorder-Related Disease By Reducing Autoreactivity In A T Cell Compartment
  • Small Peptides Which Inhibit Binding To T-4 Receptors And Act As Immunogens
  • Approach To Produce Hiv-1 Gp140 Envelope Protein Trimers
  • Antibodies Which Recognize Cd4 Epitopes That Are Present Only After Interaction With Human Immmunodeficiency Virus Gp120; For Disruption Of Virus Attachment And Entry Without Interfering With Normal Cd4 Function; Vaccines; Immunotherapy
  • Hiv Immunogenic Complexes
  • Methods For Inhibition Of Membrane-Fusion-Associated Events, Including Hepatitis B Virus Transmission
  • Method Of Purifying Authentic Trimeric Hiv-1 Gp140 Envelope Glycoproteins Comprising A Long Linker And Tag
  • Aids Virus Envelope Glycoprotein-Related Antigens, In Particular Precursors Of Such Glycoprotein, Processes For Obtaining Such Antigens, And Means Used In Such Processes, Applications Of Such Antigens To The Preparation Of Immunogen Compositions Aids Or Related Conditions
  • Producing Antibody By Immunizing Rodents Or Monkeys With Cd4-Expressing T Cells (Either Normal Or From Lymphoma- Or Leukemia-Derived Cell Lines), Forming Hybridomas; Antibody Blocks Binding Of Gp120 To Cd4 Cells, Neutralizing Virus
  • Human Monoclonal Antibodies Directed Against The Transmembrane Glycoprotein (Gp41) Of Human Immunodeficiency Virus-1 (Hiv-1)
  • Methods For Assaying Inhibition Of Hiv-1 Envelope Glycoprotein-Mediated Membrane Fusion
  • Anti-Ccr5 Antibody
  • Isolated Cytotoxic T-Cell Which Expresses A Membrane-Bound Chimeric Receptor Which Binds Target Cell And Signals To Destroy Bound Target Cell; Targets Infected, Cancerous, Tumor Or Autoimmune-Generated Cells
  • Compounds And Method Of Identifying, Synthesizing, Optimizing And Profiling Protein Modulators
  • Polynucleotide Coding Binding Polypeptide; For Use In Prevention And Treatment Of Viral Diseases And Development Of Viricides
  • Theramutein Modulators
  • Population Of Lav Virus Specific T4 Lymphocytes, Their Process For Obtaining It And Their Application To The Production Of This Virus.
  • Simian Immunodeficiency Virus Peptides With Antifusogenic And Antiviral Activities
  • Contacting With Monoclonal Antibody Which Binds To Chemokine Receptor; Blocks Fusion And Inhibits Activation Of Inflammatory Response
  • Cytokines For Use In The Prevention Of Viral Infection; Obtain Cytokine, Incubate With Viral Infected And Wild Type Cells, Detect Viral Proteins, Monitor Ability To Produce Viral Protein In Presence Of Cytokine
  • Compounds And Methods Of Identifying, Synthesizing, Optimizing And Profiling Protein Modulators
  • Methods For The Identification Of Compounds Capable Of Inhibiting Hiv-1 Viral Replication Employing Murine Cell Lines Expressing Human Topoisomerase I
  • Treating A Subject Afflicted With Hiv-1 By Administering Anti-Viral Agent Selected From A Nonnucleoside Reverse Transcriptase Inhibitor, A Nucleoside Reverse Transcriptase Inhibitor, A Hiv-1 Protease Inhibitor, And A Hiv-1 Fusion Or Viral Entry Inhibitor
  • Preventing Fusion Of Virus And Preferential Cells; Incubate Cells With Genetically Engineered Viral Particles And Viricide, Detect Reduction In Emission Energy, Reduction In Emission Indicates Prevention Of Viral Fusion And Infection
  • Monoclonal Antibody Against The Ccr5 Chemokine Receptor
  • Suppressor Of Hiv Replication And Transcription
  • Human Immunodeficiency Virus-Neutralizing Human Antibodies With Improved Breadth And Potency
  • Compounds And Methods Of Identifying, Synthesizing, Optimizing And Profiling Protein Modulators
  • Targeted Cytolysis Of Hiv-Infected Cells By Chimeric Cd4 Receptor-Bearing Cells
  • Approach To Produce Hiv-1 Gp140 Envelope Protein Trimers
  • The Retrovirus Siv Cpz-Ant And Its Uses
  • Non-Human Antigen Binding Region And A Human Constant Region; Particularly Hiv-Neutralizing, Immunoglobulins
  • Theramutein Modulators
  • Synthetic Peptide Inhibitors Of Hiv Transmission
  • Compositions And Methods For Inhibition Of Hiv-1 Infection
  • Monoclonal Antibodies And Fv Specific For Cd2 Antigen
  • Polypeptide For The Use In The Prevention On Viral Infection; Viricides
  • Methods And Compositions For Treatment Of Hiv-1 Infection Using Antiviral Compounds In Simultaneous Or Sequential Combinations
  • Antibody To Herpes Virus Entry Receptor Protein
  • Antibodies And Antibody Fragments That Specifically Bind A Cd4-Inducible Hiv Gp120 Epitope That Is Enhanced By Binding A Co-Receptor For Hiv, Such As Chemokine Receptors, Used For Inhibiting Hiv Entry Into Cells And Inhibiting Replication Of Hiv In Mammals
  • Compounds And Method Of Identifying, Synthesizing, Optimizing And Profiling Protein Modulators
  • Peptides From Transmembrane Protein, Gp41, From Human Immunodeficiency Virus; Viricides; Drug Screening; Intracellular Modulators Of Coiled-Coil Peptide Structures
  • Theramutein Modulators
  • Dual Inhibitors Of Hiv-1 Gp-120 Interactions
  • A Method Of Detecting Infectious Aids Virus
  • Methods And Compositions For Inhibition Of Membrane Fusion-Associated Events Including Rsv Transmission
  • Methods And Compositions For Inhibition Of Membrane Fusion-Associated Events, Including Hiv Transmission
  • Use In Identifying Genetic Suppressor Elements (Gses), Cellular Genes Corresponding To Such Gses, And Methods Of Using Such Cellular Genes And Their Encoded Products In Screening Assays For Selecting Additional Inhibitors Of Hiv
  • Monoclonal Antibodies Which Neutralize Hiv-1 Infection
  • Selecting And Isolating Peripheral Blood Mononuclear Cells Infected With Human Immunodeficiency Virus, Then Contacting With Specific Antibody Or Ligand Which Prevents Production Of Virus In T Cells; Viricides
  • Pharmaceutical Used For Treating Hiv Infection, The Composition And Uses Thereof
  • Immunogenic Compositions Derived From Structural Alteration Of Hiv Envelope Proteins
  • Polymorphs Of 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid Di-N-Methyl-D-Glucamine
  • Dual Inhibitors Of Hiv-1 Gp-120 Interactions
  • Has Affinity For And Binding Capability To Red Blood Cells; Nh2-Cd4-Gbp130-Cooh; Aids And Hiv
  • Chemokine Inhibition Of Immunodeficiency Virus
  • Clotting Factor-Fc Chimeric Proteins To Treat Hemophilia
  • Method Of Purifying Authentic Trimeric Hiv-1 Envelope Glycoproteins Comprising A Long Linker And Tag
  • Binding Protein For Use In Detection And Destruction Of Infectious Particles Or Cells; For Treatment Of Viral Disease, Infections And Cancer
  • Proteins Which Inhibit Hiv Infection And Replication In Vitro; Genetic Engineering
  • Human Monoclonal Antibodies Directed Against The Transmembrane Glycoprotein (Gp41) Of Human Immunodeficiency Virus-1 (Hiv-1) And Detection Of Antibodies Against Epitope (Gcsgklic)
  • Monoclonal Antibodies And Fv Specific For Cd2 Antigen
  • Selecting And Isolating Peripheral Blood Mononuclear Cells Infected With Human Immunodeficiency Virus, Then Contacting With Specific Antibody Or Ligand Which Prevents Production Of Virus In T Cells; Viricides
  • Chemokine Inhibition Of Immunodeficiency Virus
  • Anti-Hiv-1 Monoclonal Antibodies Which Bind To A Viral Epitope, Thereby Neutralizing The Virus; Antigenic/Immunogenic Linear Peptide Of Hiv-1
  • Has Affinity For And Binding Capability To Red Blood Cells; Nh2-Cd4-Gbp130-Cooh; Aids And Hiv
  • Method Of Purifying Authentic Trimeric Hiv-1 Envelope Glycoproteins Comprising A Long Linker And Tag
  • Proteins Which Inhibit Hiv Infection And Replication In Vitro; Genetic Engineering
  • Antigens Related To The Envelope Glycoprotein Of The Acquired Immunodeficiency Syndrome Virus
  • As Inhibitory Of Human And Non-Human Retroviral, Especially Human Immunodeficiency Viurs (Hiv), Transmission To Uninfected Cells
  • Designing A Soluble Full-Length Hiv-1 Gp41 Trimer
  • Vectors Expressing Hybrid Viruses, Methods Of Use And Novel Assays
  • Detecting Cd8+ By Contacting With Culture Of Cells That Contain Recombinant Dna Expression Vector In Which A Reporter Gene Is Associated With Promoter Sequence; Measuring Inhibition Of Reporter Gene; Can Use In Drugs For Aids
  • Antibodies Directed Against Cd4 For The Treatment And Functional Cure Of Hiv
  • Immunoglobulin Chimeric Monomer-Dimer Hybrids
  • Exhibit Anti-Membrane Fusion Capability, Antiviral Activity, Such As The Ability To Inhibit Hiv Transmission To Uninfected Cells
  • Comprise A Macromolecular Carrier Group Fused To A Gp41-Derived Dp178 Peptide Corresponding To Amino Acids 638 To 673 Of The Hiv-1la1 Gp41 Protein; Inhibitory Of Human And Non-Human Retroviral, Especially Hiv, Transmission To Uninfected Cells
  • Theramutein Modulators
  • Treatment Of Hiv And Other Viral Infections Using Combinatorial Therapy
  • Small Peptides Which Inhibit Binding To T-4 Receptors
  • Assay For Detection Of Viral Fusion Inhibitors
  • Immunoassay Diagnostic Kit Containing Antigens Derived From Self-Assembled, Non-Infectious, Non-Replicating, Immunogenic Retrovirus-Like Particles Comprising Modified Hiv Genomes And Chimeric Envelope Glycoproteins
  • Method Of Inducing An Immune Response Against Human Immunodeficiency Virus Comprising Administering Immunogenic Compositions Comprising Authentic Trimeric Hiv-1 Envelope Glycoproteins Containing A Long Linker And Tag
  • Stabilized Single Human Cd4 Domains And Fusion Proteins
  • Blocking Or Activation Of Endogenous Proteins Variations Rncoded By Mutated Gees
  • Substituted 3′,4′-Di-O-Camphanoyl-(+)-Cis-Khellactone Analogs, Compositions Thereof, And Methods For Using Thereof
  • Use Of Peptides For Inhibition Of Human And Non-Human Retroviral, Especially Hiv, Transmission To Uninfected Cells
  • Immunoglobulin Chimeric Monomer-Dimer Hybrids
  • The Retrovirus Siv Cpz-Ant And Its Uses
  • Hiv Immunogenic Complexes Comprising Gp120 Covalently Bound To Cd4 Or Concanavalin A
  • Authentic Trimeric Hiv-1 Envelope Glycoproteins Comprising A Long Linker And Tag
  • Anti-Ccr5 Antibody
  • Inhibitory Of Human And Non-Human Retroviral, Especially Hiv, Transmission To Uninfected Cells.
  • Detecting Modulator Of Gene Transcription; Obtain Cell, Incubate With Defective Virus, Expose To Modulator, Monitor Adjustment In Gene Expression
  • Methods For Inhibiting Hiv-1 Replication Involving The Administration Of An Anti-Ccr5 Receptor Monoclonal Antibody And Small Molecule Ccr5 Receptor Antagonist
  • Treatment And Sustained Virologic Remission Of Hiv Infection By Antibodies To Cd4 In Haart Stabilized Patients
  • Acylated Betulin And Dihydrobetulin Derivatives, Preparation Thereof And Use Thereof
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/312763a0

    DOI

    http://dx.doi.org/10.1038/312763a0

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1021684259

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/6096719


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Acquired Immunodeficiency Syndrome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antigens, Surface", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Deltaretrovirus", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptors, Virus", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "T-Lymphocytes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Vesicular stomatitis Indiana virus", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Cell and Molecular Biology Section and LRF Centre, Institute of Cancer Research, Chester Beatty Laboratories, Fulham Road, SW3 6JB, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.18886.3f", 
              "name": [
                "Cell and Molecular Biology Section and LRF Centre, Institute of Cancer Research, Chester Beatty Laboratories, Fulham Road, SW3 6JB, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dalgleish", 
            "givenName": "Angus G.", 
            "id": "sg:person.01040665311.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040665311.03"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "ICRF Human Tumour Immunology Group and Department of Haematology, University College Hospital Medical School, WC1E 6HX, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.439749.4", 
              "name": [
                "ICRF Human Tumour Immunology Group and Department of Haematology, University College Hospital Medical School, WC1E 6HX, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Beverley", 
            "givenName": "Peter C. L.", 
            "id": "sg:person.01060575403.86", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060575403.86"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cell and Molecular Biology Section and LRF Centre, Institute of Cancer Research, Chester Beatty Laboratories, Fulham Road, SW3 6JB, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.18886.3f", 
              "name": [
                "Cell and Molecular Biology Section and LRF Centre, Institute of Cancer Research, Chester Beatty Laboratories, Fulham Road, SW3 6JB, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Clapham", 
            "givenName": "Paul R.", 
            "id": "sg:person.0636250107.14", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636250107.14"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "ICRF Human Tumour Immunology Group and Department of Haematology, University College Hospital Medical School, WC1E 6HX, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.439749.4", 
              "name": [
                "ICRF Human Tumour Immunology Group and Department of Haematology, University College Hospital Medical School, WC1E 6HX, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Crawford", 
            "givenName": "Dorothy H.", 
            "id": "sg:person.0754431446.33", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754431446.33"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cell and Molecular Biology Section and LRF Centre, Institute of Cancer Research, Chester Beatty Laboratories, Fulham Road, SW3 6JB, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.18886.3f", 
              "name": [
                "Cell and Molecular Biology Section and LRF Centre, Institute of Cancer Research, Chester Beatty Laboratories, Fulham Road, SW3 6JB, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Greaves", 
            "givenName": "Melvyn F.", 
            "id": "sg:person.013377471142.72", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013377471142.72"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cell and Molecular Biology Section and LRF Centre, Institute of Cancer Research, Chester Beatty Laboratories, Fulham Road, SW3 6JB, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.18886.3f", 
              "name": [
                "Cell and Molecular Biology Section and LRF Centre, Institute of Cancer Research, Chester Beatty Laboratories, Fulham Road, SW3 6JB, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Weiss", 
            "givenName": "Robin A.", 
            "id": "sg:person.011763114607.07", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011763114607.07"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/312767a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028751316", 
              "https://doi.org/10.1038/312767a0"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1984-12", 
        "datePublishedReg": "1984-12-01", 
        "description": "Acquired immune deficiency syndrome (AIDS) is characterized by opportunistic infections and by \u2018opportunistic neoplasms\u2019 (for example, Kaposi's sarcoma)1. Persistent generalized lymphadenopathy (PGL) is epidemiologically associated with AIDS, especially in male homosexuals. A subset of T lymphocytes positive for the CD4 antigen2 (also termed T4 antigen), is depleted in AIDS and PGL patients. A retrovirus found in T-cell cultures from these patients3\u20135 is strongly implicated in the aetiology of AIDS because of the high frequency of isolation4 and the prevalence of specific antibodies6\u20138 in the patients. Here we have detected cell-surface receptors for the AIDS retrovirus (human T-cell leukaemia virus-III (HTLV-III) and lymphadenopathy-associated virus-1 (LAV-1) isolates) by testing the susceptibility of cells to infection with pseudotypes of vesicular stomatitis virus bearing retroviral envelope antigens, and by the formation of multinucleated syncytia on mixing virus-producing cells with receptor-bearing cells. Receptors were present only on cells expressing CD4 antigen; among 155 monoclonal antibodies tested, each of the 14 anti-CD4 antibodies inhibited formation of syncytia and blocked pseudotypes. Productive infection of CD4+ cells with HTLV-III or LAV-1 markedly reduced cell-surface expression of CD4. In contrast, receptors for HTLV-I and HTLV-II were not restricted to CD4+ cells, were not blocked by anti-CD4 antibodies; cells productively infected with HTLV-I and HTLV-II expressed surface CD4. Hence, we conclude that the CD4 antigen is an essential and specific component of the receptor for the causative agent of AIDS.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/312763a0", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1018957", 
            "issn": [
              "0028-0836", 
              "1476-4687"
            ], 
            "name": "Nature", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "5996", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "312"
          }
        ], 
        "keywords": [
          "anti-CD4 antibodies", 
          "CD4 antigen", 
          "HTLV-II", 
          "AIDS retrovirus", 
          "retroviral envelope antigen", 
          "immune deficiency syndrome", 
          "receptor-bearing cells", 
          "T cell cultures", 
          "etiology of AIDS", 
          "virus-producing cells", 
          "opportunistic neoplasms", 
          "formation of syncytia", 
          "opportunistic infections", 
          "HTLV-III", 
          "deficiency syndrome", 
          "cell surface expression", 
          "envelope antigen", 
          "LAV-1", 
          "surface CD4", 
          "PGL patients", 
          "CD4", 
          "vesicular stomatitis virus", 
          "male homosexuals", 
          "monoclonal antibodies", 
          "productive infection", 
          "cell surface receptors", 
          "susceptibility of cells", 
          "antigen", 
          "AIDS", 
          "infection", 
          "receptors", 
          "causative agent", 
          "antibodies", 
          "patients", 
          "stomatitis virus", 
          "HTLV", 
          "pseudotypes", 
          "cells", 
          "retroviruses", 
          "syncytia", 
          "lymphadenopathy", 
          "neoplasms", 
          "high frequency", 
          "syndrome", 
          "Kaposi", 
          "etiology", 
          "prevalence", 
          "specific components", 
          "virus", 
          "essential component", 
          "expression", 
          "agents", 
          "susceptibility", 
          "subset", 
          "homosexuals", 
          "contrast", 
          "culture", 
          "frequency", 
          "components", 
          "formation", 
          "example"
        ], 
        "name": "The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus", 
        "pagination": "763-767", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1021684259"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/312763a0"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "6096719"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/312763a0", 
          "https://app.dimensions.ai/details/publication/pub.1021684259"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:18", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_176.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/312763a0"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/312763a0'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/312763a0'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/312763a0'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/312763a0'


     

    This table displays all metadata directly associated to this object as RDF triples.

    196 TRIPLES      21 PREDICATES      96 URIs      87 LITERALS      15 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/312763a0 schema:about N1ca53983a68441e69d2ce71c2393ab50
    2 N7b7451d3ae32492abdad76f8357c1a02
    3 N7dd545d0960041ebb714c02e632f897c
    4 N90cf97dda3b94943a52fd1d34f6c931e
    5 N9aaa5e0461824c7ebb3fd0acd56d08b3
    6 Na1b02197a2e64748a160758383c3983b
    7 Nc4d7e8199e0f407a85c14e14ea8e092b
    8 Ne43cf93555b84a14a333136b9fee00e1
    9 anzsrc-for:11
    10 anzsrc-for:1107
    11 schema:author N6c727456d85f4ea484df7700128b6bf0
    12 schema:citation sg:pub.10.1038/312767a0
    13 schema:datePublished 1984-12
    14 schema:datePublishedReg 1984-12-01
    15 schema:description Acquired immune deficiency syndrome (AIDS) is characterized by opportunistic infections and by ‘opportunistic neoplasms’ (for example, Kaposi's sarcoma)1. Persistent generalized lymphadenopathy (PGL) is epidemiologically associated with AIDS, especially in male homosexuals. A subset of T lymphocytes positive for the CD4 antigen2 (also termed T4 antigen), is depleted in AIDS and PGL patients. A retrovirus found in T-cell cultures from these patients3–5 is strongly implicated in the aetiology of AIDS because of the high frequency of isolation4 and the prevalence of specific antibodies6–8 in the patients. Here we have detected cell-surface receptors for the AIDS retrovirus (human T-cell leukaemia virus-III (HTLV-III) and lymphadenopathy-associated virus-1 (LAV-1) isolates) by testing the susceptibility of cells to infection with pseudotypes of vesicular stomatitis virus bearing retroviral envelope antigens, and by the formation of multinucleated syncytia on mixing virus-producing cells with receptor-bearing cells. Receptors were present only on cells expressing CD4 antigen; among 155 monoclonal antibodies tested, each of the 14 anti-CD4 antibodies inhibited formation of syncytia and blocked pseudotypes. Productive infection of CD4+ cells with HTLV-III or LAV-1 markedly reduced cell-surface expression of CD4. In contrast, receptors for HTLV-I and HTLV-II were not restricted to CD4+ cells, were not blocked by anti-CD4 antibodies; cells productively infected with HTLV-I and HTLV-II expressed surface CD4. Hence, we conclude that the CD4 antigen is an essential and specific component of the receptor for the causative agent of AIDS.
    16 schema:genre article
    17 schema:isAccessibleForFree false
    18 schema:isPartOf N02a0e210fbbd4ae49eb65d4da4d54581
    19 Nd977c0dd57f745feb2213a0005a6a558
    20 sg:journal.1018957
    21 schema:keywords AIDS
    22 AIDS retrovirus
    23 CD4
    24 CD4 antigen
    25 HTLV
    26 HTLV-II
    27 HTLV-III
    28 Kaposi
    29 LAV-1
    30 PGL patients
    31 T cell cultures
    32 agents
    33 anti-CD4 antibodies
    34 antibodies
    35 antigen
    36 causative agent
    37 cell surface expression
    38 cell surface receptors
    39 cells
    40 components
    41 contrast
    42 culture
    43 deficiency syndrome
    44 envelope antigen
    45 essential component
    46 etiology
    47 etiology of AIDS
    48 example
    49 expression
    50 formation
    51 formation of syncytia
    52 frequency
    53 high frequency
    54 homosexuals
    55 immune deficiency syndrome
    56 infection
    57 lymphadenopathy
    58 male homosexuals
    59 monoclonal antibodies
    60 neoplasms
    61 opportunistic infections
    62 opportunistic neoplasms
    63 patients
    64 prevalence
    65 productive infection
    66 pseudotypes
    67 receptor-bearing cells
    68 receptors
    69 retroviral envelope antigen
    70 retroviruses
    71 specific components
    72 stomatitis virus
    73 subset
    74 surface CD4
    75 susceptibility
    76 susceptibility of cells
    77 syncytia
    78 syndrome
    79 vesicular stomatitis virus
    80 virus
    81 virus-producing cells
    82 schema:name The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
    83 schema:pagination 763-767
    84 schema:productId N7693f78b6bf346a6a8874adf904073b1
    85 Nc22d41f39f424fcd9fe2a478d275f1ee
    86 Nd64185aa30054aacb650bedcaa8470be
    87 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021684259
    88 https://doi.org/10.1038/312763a0
    89 schema:sdDatePublished 2022-12-01T06:18
    90 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    91 schema:sdPublisher N8fc66b8f554d47a88e83ad280f8bd85b
    92 schema:url https://doi.org/10.1038/312763a0
    93 sgo:license sg:explorer/license/
    94 sgo:sdDataset articles
    95 rdf:type schema:ScholarlyArticle
    96 N02a0e210fbbd4ae49eb65d4da4d54581 schema:volumeNumber 312
    97 rdf:type schema:PublicationVolume
    98 N0d300012b5a34eb5878109ff387b107c rdf:first sg:person.0754431446.33
    99 rdf:rest Naf13246d84814d109948264c612cccc2
    100 N1ca53983a68441e69d2ce71c2393ab50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    101 schema:name Antigens, Surface
    102 rdf:type schema:DefinedTerm
    103 N5b5e140763614c8facaec5a9d50ce25e rdf:first sg:person.0636250107.14
    104 rdf:rest N0d300012b5a34eb5878109ff387b107c
    105 N6c727456d85f4ea484df7700128b6bf0 rdf:first sg:person.01040665311.03
    106 rdf:rest Nfa57979663fa44c6b9e0a29f495ae195
    107 N7693f78b6bf346a6a8874adf904073b1 schema:name pubmed_id
    108 schema:value 6096719
    109 rdf:type schema:PropertyValue
    110 N7b7451d3ae32492abdad76f8357c1a02 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    111 schema:name Receptors, Virus
    112 rdf:type schema:DefinedTerm
    113 N7dd545d0960041ebb714c02e632f897c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    114 schema:name T-Lymphocytes
    115 rdf:type schema:DefinedTerm
    116 N8fc66b8f554d47a88e83ad280f8bd85b schema:name Springer Nature - SN SciGraph project
    117 rdf:type schema:Organization
    118 N90cf97dda3b94943a52fd1d34f6c931e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    119 schema:name Acquired Immunodeficiency Syndrome
    120 rdf:type schema:DefinedTerm
    121 N9aaa5e0461824c7ebb3fd0acd56d08b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    122 schema:name Antibodies, Monoclonal
    123 rdf:type schema:DefinedTerm
    124 Na1b02197a2e64748a160758383c3983b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    125 schema:name Deltaretrovirus
    126 rdf:type schema:DefinedTerm
    127 Naf13246d84814d109948264c612cccc2 rdf:first sg:person.013377471142.72
    128 rdf:rest Ne0aa241b3ce544a79d4df4b8a4dbe687
    129 Nc22d41f39f424fcd9fe2a478d275f1ee schema:name dimensions_id
    130 schema:value pub.1021684259
    131 rdf:type schema:PropertyValue
    132 Nc4d7e8199e0f407a85c14e14ea8e092b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    133 schema:name Humans
    134 rdf:type schema:DefinedTerm
    135 Nd64185aa30054aacb650bedcaa8470be schema:name doi
    136 schema:value 10.1038/312763a0
    137 rdf:type schema:PropertyValue
    138 Nd977c0dd57f745feb2213a0005a6a558 schema:issueNumber 5996
    139 rdf:type schema:PublicationIssue
    140 Ne0aa241b3ce544a79d4df4b8a4dbe687 rdf:first sg:person.011763114607.07
    141 rdf:rest rdf:nil
    142 Ne43cf93555b84a14a333136b9fee00e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Vesicular stomatitis Indiana virus
    144 rdf:type schema:DefinedTerm
    145 Nfa57979663fa44c6b9e0a29f495ae195 rdf:first sg:person.01060575403.86
    146 rdf:rest N5b5e140763614c8facaec5a9d50ce25e
    147 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    148 schema:name Medical and Health Sciences
    149 rdf:type schema:DefinedTerm
    150 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    151 schema:name Immunology
    152 rdf:type schema:DefinedTerm
    153 sg:journal.1018957 schema:issn 0028-0836
    154 1476-4687
    155 schema:name Nature
    156 schema:publisher Springer Nature
    157 rdf:type schema:Periodical
    158 sg:person.01040665311.03 schema:affiliation grid-institutes:grid.18886.3f
    159 schema:familyName Dalgleish
    160 schema:givenName Angus G.
    161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040665311.03
    162 rdf:type schema:Person
    163 sg:person.01060575403.86 schema:affiliation grid-institutes:grid.439749.4
    164 schema:familyName Beverley
    165 schema:givenName Peter C. L.
    166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060575403.86
    167 rdf:type schema:Person
    168 sg:person.011763114607.07 schema:affiliation grid-institutes:grid.18886.3f
    169 schema:familyName Weiss
    170 schema:givenName Robin A.
    171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011763114607.07
    172 rdf:type schema:Person
    173 sg:person.013377471142.72 schema:affiliation grid-institutes:grid.18886.3f
    174 schema:familyName Greaves
    175 schema:givenName Melvyn F.
    176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013377471142.72
    177 rdf:type schema:Person
    178 sg:person.0636250107.14 schema:affiliation grid-institutes:grid.18886.3f
    179 schema:familyName Clapham
    180 schema:givenName Paul R.
    181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636250107.14
    182 rdf:type schema:Person
    183 sg:person.0754431446.33 schema:affiliation grid-institutes:grid.439749.4
    184 schema:familyName Crawford
    185 schema:givenName Dorothy H.
    186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754431446.33
    187 rdf:type schema:Person
    188 sg:pub.10.1038/312767a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028751316
    189 https://doi.org/10.1038/312767a0
    190 rdf:type schema:CreativeWork
    191 grid-institutes:grid.18886.3f schema:alternateName Cell and Molecular Biology Section and LRF Centre, Institute of Cancer Research, Chester Beatty Laboratories, Fulham Road, SW3 6JB, London, UK
    192 schema:name Cell and Molecular Biology Section and LRF Centre, Institute of Cancer Research, Chester Beatty Laboratories, Fulham Road, SW3 6JB, London, UK
    193 rdf:type schema:Organization
    194 grid-institutes:grid.439749.4 schema:alternateName ICRF Human Tumour Immunology Group and Department of Haematology, University College Hospital Medical School, WC1E 6HX, London, UK
    195 schema:name ICRF Human Tumour Immunology Group and Department of Haematology, University College Hospital Medical School, WC1E 6HX, London, UK
    196 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...